Shots:

• Exservan (riluzole) Oral Film received the US FDA approval and has also received FDA’s ODD in Jan 2019 and has been evaluated to assess PK bioequivalence to the Rilutek
• The ODD is granted to novel drugs and biologics which are intended for the safe and effective treatment- diagnosis or prevention of rare diseases affecting people less than 200-000 in the US
• Exservan (50mg) is an Oral film formulation of approved glutamate Inhibitor riluzole applied on top of the tongue where it adheres and dissolves

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Twitter